RPTX
Price:
$2.81
Market Cap:
$119.46M
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 ...[Read more]
Industry
Biotechnology
IPO Date
2020-06-19
Stock Exchange
NASDAQ
Ticker
RPTX
According to Repare Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.41. This represents a change of 436.84% compared to the average of -0.26 of the last 4 quarters.
The mean historical PE Ratio of Repare Therapeutics Inc. over the last ten years is -27.66. The current -1.41 PE Ratio has changed 409.83% with respect to the historical average. Over the past ten years (40 quarters), RPTX's PE Ratio was at its highest in in the March 2024 quarter at 3.77. The PE Ratio was at its lowest in in the March 2019 quarter at -36.91.
Average
-27.66
Median
-23.70
Minimum
-62.38
Maximum
-3.28
Discovering the peaks and valleys of Repare Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 184.57%
Maximum Annual PE Ratio = -3.28
Minimum Annual Increase = -84.57%
Minimum Annual PE Ratio = -62.38
Year | PE Ratio | Change |
---|---|---|
2023 | -3.28 | -84.57% |
2022 | -21.23 | 184.57% |
2021 | -7.46 | -68.52% |
2020 | -23.70 | -42.90% |
2019 | -41.50 | 21.87% |
2018 | -34.05 | -45.42% |
The current PE Ratio of Repare Therapeutics Inc. (RPTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.66
5-year avg
-19.43
10-year avg
-27.66
Repare Therapeutics Inc.’s PE Ratio is greater than Accolade, Inc. (-3.70), greater than Nurix Therapeutics, Inc. (-9.07), greater than 908 Devices Inc. (-1.47), greater than Relay Therapeutics, Inc. (-1.93), greater than Fusion Pharmaceuticals Inc. (-17.31),
Company | PE Ratio | Market cap |
---|---|---|
-3.70 | $297.99M | |
-9.07 | $1.56B | |
-1.47 | $89.15M | |
-1.93 | $795.07M | |
-17.31 | $1.83B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Repare Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Repare Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Repare Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for Repare Therapeutics Inc. (RPTX)?
What is the highest PE Ratio for Repare Therapeutics Inc. (RPTX)?
What is the 3-year average PE Ratio for Repare Therapeutics Inc. (RPTX)?
What is the 5-year average PE Ratio for Repare Therapeutics Inc. (RPTX)?
How does the current PE Ratio for Repare Therapeutics Inc. (RPTX) compare to its historical average?